In this scenario, the ET-1 peptide secreted by CLL cells or by other cell types, such as endothelial cells inside infiltrated tissues, could interfere with the effect of novel molecules currently undergoing clinical trial with promising results [16], [37]. This evidence concerns the gene EDN1 and B-cell chronic lymphocytic leukemia.